Loading organizations...
§ Private Profile · Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark
Biotech spin-out developing protein degradation therapies harnessing the lysosome for arthritis and dementia.
Draupnir Bio ApS has raised $13.1M across 1 funding round.
Key people at Draupnir Bio ApS.
Draupnir Bio ApS has raised $13.1M in total across 1 funding round.
Draupnir Bio ApS is a biotechnology company based in Copenhagen, Denmark, that develops targeted protein degradation therapies utilizing the lysosome's natural machinery to selectively clear harmful proteins. The enterprise focuses on creating treatments for severe conditions such as arthritis, neurological disorders, and dementia through proprietary technology that enables the body to eliminate problematic proteins. Operating as a venture backed spinout from Aarhus University and the Max Planck Society, the firm has secured seed and Series A financing to advance its pipeline of PROTAC therapeutics. The organization is financially supported by a syndicate of at least five prominent life sciences investors, including Gilde Healthcare Partners, Inkef Capital, Novo Seeds, MP Healthcare Venture Management, and EIFO. Draupnir Bio ApS was founded between 2017 and 2021 by the team of Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger.
Key people at Draupnir Bio ApS.
Draupnir Bio ApS has raised $13.1M in total across 1 funding round.
Draupnir Bio ApS has raised $13.1M across 1 funding round. Most recently, it raised $13.1M Draupnir Bio - Seed in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 22, 2024 | $13.1M Seed | — | — | Announced |
Draupnir Bio ApS is a Danish biotechnology company developing oral, small-molecule degraders of extracellular and membrane-bound pathogenic proteins using a proprietary lysosome-targeting platform.[1][2][4][5] Incorporated in Denmark in 2017 with registration number 38546880, it focuses on pioneering targeted protein degradation (TPD) beyond intracellular targets, with its lead SORTAC (sortilin-based lysosome targeting chimera) technology targeting sortilin receptors for broad therapeutic applications, including cardiovascular diseases via glycan mimetics and other hard-to-drug proteins.[2][4][5] The company serves patients with unmet needs in multiple disease areas by harnessing lysosomal machinery for protein degradation, backed by investors like Gilde Healthcare Partners, Inkef Capital, Novo Seeds, and MP Healthcare Venture Management, and maintains an active UK establishment since June 2021.[1][4]
Draupnir Bio emerged as a spin-out from Aarhus University in 2017, initially developing a platform based on array technology, protein chemistry, and advanced carbohydrate chemistry to explore the glycome for novel therapeutics.[2] Its evolution shifted toward extending TPD to extracellular proteins, leveraging a proprietary SORTAC technology that uses sortilin receptors for cellular uptake and lysosomal degradation of disease proteins.[4][5] Early traction built on university research, with the company now led by experienced pharma and biotech leaders, filing accounts up to December 2023 and operating from Symbion Fuglebakken in Frederiksberg, Denmark.[1][4]
Draupnir Bio rides the targeted protein degradation (TPD) wave, expanding it from intracellular to extracellular domains amid growing demand for oral small-molecule therapies against undruggable targets.[4][5] Timing aligns with advances in lysosomal biology and investor interest in next-gen biotech, as traditional antibodies falter for extracellular proteins; market forces like rising cardiovascular burdens and TPD's projected multi-billion-dollar potential favor its SORTAC platform.[2][5] It influences the ecosystem by validating lysosome receptors (e.g., sortilin) for broad tissue applicability, inspiring spin-outs from academia like Aarhus University and accelerating Europe's biotech innovation.[1][2][4]
Draupnir Bio is poised to advance its preclinical pipeline into clinical stages, prioritizing SORTAC degraders for high-impact indications like cardiovascular disease while expanding to other extracellular targets.[4][5] Trends in oral TPD, lysosomal targeting, and AI-driven target validation will propel its growth, potentially disrupting large markets dominated by biologics. Its influence may evolve from platform pioneer to multi-asset leader, delivering innovative therapies and reinforcing Denmark's biotech hub status—extending the TPD frontier first glimpsed in its glycome origins.[2][4][5]
